155 related articles for article (PubMed ID: 24682510)
1. Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase.
Tong WH; Pieters R; Tissing WJ; van der Sluis IM
Haematologica; 2014 Jul; 99(7):e102-4. PubMed ID: 24682510
[No Abstract] [Full Text] [Related]
2. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
4. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
5. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
6. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
8. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
Kloos R; van der Sluis IM; Mastrobattista E; Hennink W; Pieters R; Verhoef JJ
Br J Haematol; 2020 May; 189(3):442-451. PubMed ID: 31883112
[TBL] [Abstract][Full Text] [Related]
9. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
11. Shedding light on the asparaginase galaxy.
Rizzari C
Blood; 2014 Mar; 123(13):1976-8. PubMed ID: 24677398
[TBL] [Abstract][Full Text] [Related]
12. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication.
Losasso M; Bostrom B; Messinger Y
F1000Res; 2019; 8():1007. PubMed ID: 32089823
[No Abstract] [Full Text] [Related]
13. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
14. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
15. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
[TBL] [Abstract][Full Text] [Related]
17. A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
Kloos RQH; Uyl-de Groot CA; van Litsenburg RRL; Kaspers GJL; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28766887
[TBL] [Abstract][Full Text] [Related]
18. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
19. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Vyas C; Jain S; Kapoor G; Mehta A; Takkar Chugh P
Pediatr Hematol Oncol; 2018; 35(5-6):331-340. PubMed ID: 30488741
[TBL] [Abstract][Full Text] [Related]
20. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
Dam M; Centanni M; Friberg LE; Centanni D; Karlsson MO; Stensig Lynggaard L; Johannsdottir IM; Wik HS; Malmros J; Vaitkeviciene GE; Griskevicius L; Hallböök H; Jónsson ÓG; Overgaard U; Schmiegelow K; Hansen SN; Heyman M; Albertsen BK
Leukemia; 2024 Apr; 38(4):712-719. PubMed ID: 38287133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]